Listen to the article
In a closely watched hearing Wednesday, Third Circuit judges appeared hesitant to upend the False Claims Act’s whistleblower provisions while evaluating arguments regarding the landmark fraud verdict against Johnson & Johnson.
The panel’s deliberations could have far-reaching implications for one of the government’s most powerful fraud-fighting tools and for J&J, which faces substantial financial penalties from the record judgment.
During oral arguments, the three-judge panel engaged with attorneys from both sides, examining constitutional challenges to the False Claims Act’s qui tam provisions, which allow private citizens to file lawsuits on behalf of the government and share in any recovery. These provisions have been the cornerstone of the FCA since its Civil War-era origins but have faced increasing scrutiny in recent years.
The case stems from allegations that Johnson & Johnson, one of the world’s largest healthcare companies, violated federal regulations and submitted false claims to government healthcare programs. The previous verdict represents one of the largest FCA judgments in U.S. history, potentially subjecting J&J to hundreds of millions in damages.
Several judges expressed skepticism toward arguments that would invalidate the whistleblower mechanism that has recovered more than $70 billion for taxpayers since 1986 amendments strengthened the law. One judge noted that “dismantling a system with such a proven track record of protecting government funds would require extraordinarily compelling constitutional grounds.”
The Department of Justice, which intervened in the case, defended the FCA’s structure, arguing that whistleblower provisions serve as a critical extension of the government’s limited enforcement resources. A DOJ attorney emphasized that the executive branch maintains sufficient control over qui tam actions through various statutory provisions, including the right to intervene and dismiss cases.
Johnson & Johnson’s legal team, however, argued that the qui tam provisions violate Article II of the Constitution by improperly delegating executive power to private individuals who lack proper oversight and accountability. They pointed to recent Supreme Court decisions questioning similar delegations of government authority to private parties.
Legal experts watching the case note that challenges to the FCA’s constitutionality have gained traction in recent years, particularly following the Supreme Court’s 2023 decision in U.S. ex rel. Polansky v. Executive Health Resources, which addressed government dismissal authority in qui tam cases.
“The Third Circuit’s ruling could either reinforce the FCA as currently structured or signal the need for legislative reform,” said Elizabeth Harrington, a healthcare fraud expert at Washington University Law School. “Given that FCA recoveries represent billions in annual recoveries for the government, the stakes couldn’t be higher.”
For Johnson & Johnson, the case represents just one of several major legal challenges the company faces. The healthcare giant continues to navigate litigation related to its talc products, opioid medications, and other healthcare offerings.
The pharmaceutical industry has long criticized the FCA’s whistleblower provisions as creating excessive compliance burdens and unpredictable liability risks. Industry representatives argue that technical regulatory violations can be transformed into massive fraud claims under the current system, often driven by whistleblowers and their attorneys seeking substantial rewards.
Patient advocacy groups and taxpayer watchdogs, however, submitted amicus briefs supporting the FCA’s current structure, arguing it provides necessary accountability in the heavily regulated and government-funded healthcare sector.
The Third Circuit’s decision, expected later this year, could potentially reshape how the government pursues fraud cases against healthcare providers, defense contractors, and other recipients of federal funds. A ruling against the qui tam provisions would likely trigger immediate appeals to the Supreme Court and potential congressional intervention to redesign the statute.
Whatever the outcome, the case highlights the ongoing tension between effective fraud enforcement and constitutional limitations on delegating government powers—a balance that has implications far beyond Johnson & Johnson or the healthcare industry.
Fact Checker
Verify the accuracy of this article using The Disinformation Commission analysis and real-time sources.
8 Comments
As a major case involving the False Claims Act, this will certainly be closely watched. The Third Circuit’s ruling could have far-reaching impacts on how the government and whistleblowers approach corporate misconduct going forward.
Absolutely, the outcome here could set important precedents for FCA enforcement. It’s a complex issue requiring careful consideration by the courts.
The constitutional challenges to the FCA’s qui tam provisions are an interesting legal angle. It will be important for the court to balance the law’s fraud-fighting power with any potential overreach or procedural concerns.
A $1.6 billion penalty against a major healthcare company like J&J is no small matter. This case highlights the high stakes involved when the government pursues FCA violations, and the need for careful judicial review of the law’s mechanisms.
The False Claims Act has been crucial for uncovering fraud against government healthcare programs. While the constitutionality of the qui tam provisions is being questioned, the act’s role in fighting corporate misconduct shouldn’t be underestimated.
Agreed. The FCA has been an important check on companies trying to game the system. Maintaining its effectiveness will be crucial, even if some refinements are needed.
This case could have major implications for the future of the False Claims Act and how whistleblowers can hold large companies accountable. It will be interesting to see how the Third Circuit judges rule on the constitutional challenges.
Johnson & Johnson facing such a substantial penalty is certainly eye-catching. The FCA has been a powerful tool, but the increasing scrutiny on its qui tam provisions shows there are still debates to be had around its proper scope and application.